Baillie Gifford & Co. Trims Stock Position in Health Catalyst, Inc. (NASDAQ:HCAT)

Baillie Gifford & Co. lessened its stake in Health Catalyst, Inc. (NASDAQ:HCAT) by 71.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 121,855 shares of the company’s stock after selling 308,742 shares during the period. Baillie Gifford & Co.’s holdings in Health Catalyst were worth $992,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. First Light Asset Management LLC boosted its position in shares of Health Catalyst by 438.5% in the 2nd quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock valued at $25,279,000 after purchasing an additional 3,221,408 shares during the period. Millennium Management LLC lifted its stake in Health Catalyst by 96.3% in the second quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock valued at $15,421,000 after buying an additional 1,184,131 shares during the last quarter. Kennedy Capital Management LLC acquired a new stake in shares of Health Catalyst in the first quarter valued at approximately $8,780,000. Nepsis Inc. grew its position in shares of Health Catalyst by 67.9% during the third quarter. Nepsis Inc. now owns 2,104,528 shares of the company’s stock worth $17,131,000 after acquiring an additional 851,448 shares during the last quarter. Finally, Impax Asset Management Group plc increased its holdings in shares of Health Catalyst by 16.4% in the 3rd quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock valued at $20,793,000 after acquiring an additional 360,201 shares during the period. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Analyst Ratings Changes

HCAT has been the subject of a number of recent research reports. Piper Sandler decreased their price target on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 26th. Evercore ISI increased their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. Stephens dropped their price target on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 8th. Citigroup upped their price objective on Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a research note on Wednesday. Finally, JPMorgan Chase & Co. lifted their target price on Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, September 4th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $11.54.

Insider Activity

In other Health Catalyst news, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the transaction, the insider now directly owns 255,881 shares in the company, valued at approximately $1,847,460.82. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the sale, the insider now owns 255,881 shares of the company’s stock, valued at approximately $1,847,460.82. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Daniel Lesueur sold 5,209 shares of the firm’s stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $7.68, for a total value of $40,005.12. Following the transaction, the chief operating officer now directly owns 134,899 shares of the company’s stock, valued at $1,036,024.32. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 34,068 shares of company stock worth $257,555. Company insiders own 2.50% of the company’s stock.

Health Catalyst Trading Up 6.5 %

NASDAQ:HCAT opened at $8.66 on Thursday. Health Catalyst, Inc. has a 1 year low of $5.42 and a 1 year high of $11.41. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The stock has a fifty day moving average price of $8.11 and a two-hundred day moving average price of $7.19. The stock has a market capitalization of $526.96 million, a price-to-earnings ratio of -6.55 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company had revenue of $76.40 million during the quarter, compared to analysts’ expectations of $76.27 million. During the same quarter in the prior year, the business earned ($0.22) EPS. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Health Catalyst, Inc. will post -0.35 earnings per share for the current fiscal year.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.